Financials data is unavailable for this security.
View more
Year on year Oncolys Biopharma Inc 's revenues fell -93.54% from 976.18m to 63.04m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 1.15bn to a larger loss of 1.94bn.
Gross margin | 0.00% |
---|---|
Net profit margin | -5,813.82% |
Operating margin | -5,876.45% |
Return on assets | -97.25% |
---|---|
Return on equity | -134.78% |
Return on investment | -116.54% |
More ▼
Cash flow in JPYView more
In 2023, cash reserves at Oncolys Biopharma Inc fell by 178.44m. Cash Flow from Financing totalled 1.14bn or 1,812.47% of revenues. In addition the company used 1.34bn for operations while cash used for investing totalled 5.39m.
Cash flow per share | -94.19 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 67.90 |
---|---|
Tangible book value per share | 67.90 |
More ▼
Balance sheet in JPYView more
Current ratio | 7.03 |
---|---|
Quick ratio | 7.01 |
Total debt/total equity | 0.2582 |
---|---|
Total debt/total capital | 0.2052 |
More ▼